ESPRM 2018 | VILNIUS LITHUANIA to view the content of this newsletter on your browser, please click here
| |
---|
|
---|
| Are you interested in rehabilitation and how to measure functioning in persons with genetic muscular dystrophies?You may learn how to choose outcome measure, strategies to validate trials using new genetic therapies in persons with genetic muscular dystrophiesProfessor François Constant BOYER and Ghilas BOUSSAID with Algirdas UTKUS and Andoni URTIZBEREAinvite you to VilniusJoint session AFM - ESPRM (AFM-Téléthon - The French Muscular Dystrophy Association and European Society of Physical and Rehabilitation Medicine)Rehabilitation of rare disease and muscular dystrophies: outcome measures preparing genetic therapiesSESSION ON: “ Persons with Genetic Neuromuscular Disease ” Thursday May 3, 2018; Room Zeta : 17.00 - 19.00CHAIRPERSONS: François Constant BOYER, Ghilas BOUSSAID, Algirdas UTKUS, Andoni URTIZBERA SPEAKERS: Laurent SERVAIS Clinical trial and outcome measures in Neuromuscular Disorders Pisco DOMINGOS Outcome measures in Duchenne muscular dystrophy and implications for clinical trials Enzo RICCI Muscle MRI as an outcome measure in neuromuscular diseases Carole VUILLEROT MFM measure and NMD: metrological powers Antoine DANY, François Constant BOYER Qol-gNMD, a new patient reported outcome measures validated with a Rasch model theory |
---|
|
---|
For more information visit www.esprm2018.com Newsletter prepared by François Constant BOYER and Jolanta KUJAWA. To unsubscribe from receiving this newsletter click here | |
---|
|
---|
|
|